Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ...

A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. For more information about these conferences ...

Pharming Group excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow. Check out my recommendation for PHAR stock.

Pharming Group delivered strong financial results in Q4 2024 and provided an optimistic 2025 revenue guidance of $315 million to $335 million, driven by the continued success of RUCONEST and Joenja.

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pharming Group (PHAR – Research Report) today and set a price target of ...

Across the recent three months, 4 analysts have shared their insights on Pharming PHAR, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ...

Good day and thank you for standing by. Welcome to the Pharming Group Fourth Quarter and Full-year 2024 Results Conference Call and Webcast. [Operator Instructions] Please be advised that today's ...

The latest price target for Pharming (NASDAQ:PHAR) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $37.00 expecting PHAR to rise to within 12 months ...

The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20-F can be found under ...

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will ...